Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis' world-leading biocatalyst technology within...
EnzymeWorks has been ordered by the United States District Court for the Northern District of California to retract its prior statements and press releases pertaining in any way to the settlement...
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners,...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in...
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 9:50 a.m....
Origenis GmbH, a German biotech company specializing in the discovery and development of highly selective small molecule kinase inhibitors for CNS disorders, today announced the appointment...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Codexis, Inc. (NASDAQ: CDXS) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time.
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018. Codexis...
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding...
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved DNA ligase for the molecular diagnostics industry...
Product sales increase 71% over the prior year
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Codexis, Inc. (NASDAQ: CDXS) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM Eastern Time.
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two investment conferences in November:
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2017 financial results after market close on Thursday, November 9, 2017. Codexis management...
-- Includes an option for the global development of CDX-6114 for PKU, marking Codexis' first partnership for an internally developed biotherapeutic product. Codexis receives an upfront payment of $14...
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at four investment conferences in September:
In response to a recent inaccurate press release by Codexis regarding the case Codexis, Inc. v. EnzymeWorks, Inc., Case No. 3:16-cv-00826-WHO (the "Case"), EnzymeWorks and Alex Tao, Ph.D.,...
Product sales more than doubled versus prior-year second quarter
NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Codexis, Inc. (NASDAQ: CDXS) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 at 4:30 PM Eastern...
